Table 2. The associations of the selected markers of the TNMD gene with exudative AMD in men.
| Marker | Genotype | Number of cases/controls | OR (95%CI) | p |
|---|---|---|---|---|
|
rs7890586 |
GG |
78/41 |
1 (reference) |
0.112 |
| AA |
11/12 |
0.482 (0.196–1.187) |
||
|
rs11798018 |
CC |
58/31 |
1 (reference) |
0.292 |
| AA |
31/24 |
0.690 (0.347–1.374) |
||
|
rs5966709 |
GG |
57/31 |
1 (reference) |
0.359 |
| TT |
32/24 |
0.725 (0.362–1.441) |
||
|
rs2073163 |
TT |
60/41 |
1 (reference) |
0.365 |
| CC |
29/14 |
1.415 (0.668–3.001) |
||
|
rs1155974 |
CC |
60/36 |
1 (reference) |
0.808 |
| TT |
29/19 |
0.916 (0.450–1.864) |
||
| rs1204384 | AA |
61/39 |
1 (reference) |
0.84 |
| TT | 27/16 | 1.079 (0.516–2.256) | ||
Abbreviations: odds ratio (OR); confidence interval (CI). None of the markers was associated with the prevalence of AMD in men.